2 results
Approved WMOCompleted
The primary efficacy endpoint is treatment success in the therapy for mild to moderate Crohn*s disease with fisultas defined by: - A reduction of at least 50% in the number of draining fistulas at both week 4 and week 8
Approved WMORecruiting
Our primary objective is to assess the effect of diltiazem on coronary microvascular function as assessed by coronary reactivity testing in symptomatic patients with CMD.